Khalid Islam, PhD, Chairman

Dr. Khalid Islam is the founder and current Chairman of KI Consulting AG, a consulting firm specializing in the development of pharmaceutical drugs. Dr. Islam is also the co-founder of Sirius Healthcare Partners, an advisory firm for mid-cap and small-cap life science companies. From July 1999 until May 2008 Dr. Islam was the President and Chief Executive Officer for Arpida AG, a Swiss biopharmaceutical company that focuses on novel products for the treatment of microbial infections. Prior to that, Dr. Islam worked as an Alliance Manager for Hoechts Marion Roussel, a global pharmaceutical company, where he assisted with drug discovery and development. Dr. Islam has extensive experience working on behalf of pharmaceutical companies with both the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) and has been involved with the development and marketing of several pharmaceutical products. Dr. Islam has previously served as a member of the Board of Directors for Arpida AG, Rheoscience A/S, and Arpida Inc. Dr. Islam received a B.S. in Biochemistry from Chelsea College, University of London, in 1977 and his Ph.D. from Imperial College, University of London, in 1983.


Stephan Christgau, PhD

Prior to joining Novo Seeds, Dr Christgau was Executive Vice President and Chief Operating Officer at Osteologix where he played a leading role in the development of the company, taking the lead candidate drug through all stages from lead identification to Phase II testing for osteoporosis treatment. He also played an active role in the company’s financing including a public listing in the USA on the OTC exchange through a reverse merger with a public shell company. Previously Dr Christgau worked in the metabolic bone disease and arthritis areas in Nordic Bioscience and Osteometer Biotech and as a protein chemist in Novo Nordisk A/S. Dr Christgau is the author of more than 60 scientific publications and inventor on more than 30 patent families. Dr Christgau serves on the board of directors of EpiTherapeutics ApS and Inagen ApS, both Danish based biotech companies.


Anker Lundemose, MD

Serial biotech entrepreneur and co-founder of several biotech companies including Symphogen A/S, Prosidion Ltd in the UK and Santaris Pharma A/S. Background spans academia, large pharma as well as biotech with positions held in R&D, Business & Corporate Development as well as Executive Management. International track record in R&D productivity & deal making including execution of high impact license agreements as well as significant M&A transactions. Former managing director of OSI Pharmaceutical’s venture arm in Switzerland which has invested in several biotech companies including Danish Epitherapeutics A/S. Previously held positions at OSI Pharmaceuticals Inc., Prosidion Ltd., Novo Nordisk and has served as member of the Board of Directors for Symphogen, Prosidion Ltd, OSI Pharmaceuticals UK Limited, OSI Investment Holding GmbH & OSI Investment Management GmbH and for Display Biotech Systems. Dr Lundemose is a Medical Doctor from University of Aarhus, and holds Ph.D. degree in Molecular Microbiology and a degree as Doctor of Medical Science (Dr. med.), both from University of Aarhus.



Andreas Seggeros, MBA

Andreas Segerros, a biochemist by training, majoring in biopolymers, from the Royal Institute of Technology in Stockholm and an MBA from Uppsala University. He started at Pharmacia where he spent most of his career. That included senior marketing and business development positions within the Specialty Pharma divisions at the Corporate Office. He headed up the company’s Ophthalmology franchise in the USA and Japan for many years. The Pharmacia years led to valuable experiences of portfolio management and mergers. He has also experienced the life science upstart environment as CEO for Clinitrac, a provider of enabling technologies for pharmaceutical development. Most recently Andreas was Head of Business Development and Operations Planning at Ferring Pharmaceuticals, headquartered in Switzerland. Today, he is a Partner at Sunstone Capital, and advisor to the Swiss biotech Evolva.



Paul Goldenheim, MD

Dr. Goldenheim is the CEO of Adenium Biotech and he joined the Board of Directors in January 2015.










Adenium Biotech ApS | Ole Maaloesvej 3 | 2200 Copenhagen N | Denmark | CVR 33882785